News | April 02, 2024
Apotex to acquire Canadian Searchlight Pharma
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
The average time of dilation lasts three to eight hours
Application based on results from the TROPION-Breast01 Phase III trial
This acquisition enables MTD to open new, strategic markets
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The company had earlier announced about the approval received from the MHRA for Liraglutide
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Subscribe To Our Newsletter & Stay Updated
